The interface between the EGF2 domain and the protease domain in blood coagulation factor IX contributes to factor VIII binding and factor X activation.
The light chain of activated factor IX (FIXa) is involved in a number of functional properties, including FIXa enzymatic activity. This suggests the existence of a functional link between the FIXa light chain and the catalytic domain. The FIXa structure includes a few putative interactions between EGF2 and the protease domain. The role thereof has been addressed in this study. Recombinant FIX variants FIX-N92A, FIX-N92H, FIX-Y295A, and FIX-F299A were produced in 293 cells. After activation, the purified mutants were analyzed for a variety of functional parameters. None of these substitutions had a major effect on the interaction with antithrombin or the cleavage of the chromogenic substrate CH(3)SO(2)-d-CHG-Gly-Arg-p-nitroanilide. All FIXa mutants, however, exhibited a reduced level of factor X (FX) activation. Defective proteolytic activity occurred both in the absence and in the presence of activated factor VIII (FVIIIa). All mutants also exhibited a reduced level of FX activation in the absence of phospholipids. This suggests that putative interdomain contacts involving residues Asn(92), Tyr(295), and Phe(299) affect reactivity toward FX. Detailed kinetic studies in the presence of phospholipids and FVIIIa revealed substrate inhibition, particularly for mutants FIXa-N92A and FIXa-N92H. Surface plasmon resonance demonstrated that the same replacements weaken the association with the isolated factor VIII (FVIII) A2 domain and the FVIII light chain. This implies a defect in the formation of the FX-activating complex that is membrane-independent. We conclude that contacts between EGF2 and the protease domain of FIXa are crucial for FIXa enzymatic activity and for the assembly of the FX-activating complex.
Fribourg
Caroline
C
Department of Plasma Proteins, Sanquin Research, 1066 CX Amsterdam, The Netherlands.
Meijer
Alexander B
AB
Mertens
Koen
K
D000627:Aminophenols / Q000737:chemistry; D000991:Antithrombins / Q000737:chemistry / Q000494:pharmacology; D001665:Binding Sites; D002460:Cell Line; D004789:Enzyme Activation; D004815:Epidermal Growth Factor / Q000737:chemistry*; D005164:Factor IX / Q000737:chemistry* / Q000235:genetics; D005169:Factor VIII / Q000737:chemistry*; D005170:Factor X / Q000737:chemistry*; D006801:Humans; D007700:Kinetics; D008954:Models, Biological; D010447:Peptide Hydrolases / Q000737:chemistry*; D011485:Protein Binding; D017434:Protein Structure, Tertiary; D013329:Structure-Activity Relationship
D000627:Aminophenols; D000991:Antithrombins; D004815:Epidermal Growth Factor; D005169:Factor VIII; D005164:Factor IX; D005170:Factor X; D010447:Peptide Hydrolases; C034362:2,4-diaminophenol